Company intelligence
InoRx
Contract Research Organization accelerating Phase I–IV biotech & pharma trials through India's integrated site network.
About InoRx
InoRx is a next-generation Contract Research Organization (CRO) built to accelerate clinical development through innovation, patient access, and operational excellence. Headquartered in the U.S. with operations in India, InoRx leverages its affiliate network of academic medical centers and clinics, high quality standards, and experienced clinical operations, to deliver faster, more cost effective, highly reliable clinical studies for sponsors worldwide. Backed by SRM Group InoRx is part of the SRM Group, a diversified global enterprise with $1.4 billion in revenue and thousands of employees across healthcare, education, technology, and more. SRM’s decades of experience and reputation in medical research, hospital systems, and academic excellence provide InoRx with scientific expertise, infrastructure, and access to a vast network of clinicians, research sites, and patients.
Verified activity
Signals from InoRx
8 published signals
Strategy & Corporate Development
InoRx notes that in May 2024, ICMR, India's apex biomedical research agency signed five-year agreements creating a national Phase 1 network at four hospitals, chosen competitively from thirty eligible applicants.
Reported by Christopher Macri
Strategy & Corporate Development
InoRx highlights that India is the answer almost nobody is using, with ClinicalTrials.gov listing 485 recruiting interventional studies with a site in India.
Reported by Christopher Macri
Legal & Regulatory
InoRx notes that by late August, two House members had asked the FDA to stop accepting China-generated clinical data unless the agency had inspected the site within the previous twelve months.
Reported by Christopher Macri
Customers & Market
InoRx delivered site activation and Ethics Committee approval for a Phase I healthy-volunteer study of a rheumatoid arthritis molecule after a previous CRO struggled with a new Central Drugs Standard Control Organization (CDSCO) requirement for government site sourcing.
Reported by InoRx
Operations & Supply
InoRx owns 500+ vetted clinical sites and 800+ clinicians and Principal Investigators, backed by direct access to SRM Medical College Hospital and Research Centre, SRM Institute of Science and Technology, and SRM GROUP system.
Reported by InoRx
Research & Knowledge
InoRx published three case studies detailing the recovery of clinical trials, including a Phase 1 rheumatoid arthritis study requiring half the population to come from a Phase 1 site recognized by ICMR.
Reported by Christopher Macri
Research & Knowledge
InoRx published a 2,000-participant medical device study that wasn't a speed problem at all.
Reported by Christopher Macri
Research & Knowledge
InoRx published a bioequivalence study in an anemic population where the previous CRO couldn't open eight planned sites on time.
Reported by Christopher Macri